The tolerability and safety of cholinesterase inhibitors in the treatment of dementia

International Journal of Clinical Practice, Supplement

Volumn , Issue 127, 2002, Pages 45-63

  Inglis, F ^a  

^a Glasgow Memory Clinic   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Donepezil; Galantamine; Rivastigmine; Safety; Tolerability

Indexed keywords

ACETYLCHOLINESTERASE; ANALGESIC AGENT; ANTACID AGENT; ANTIDIABETIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGITALIS; DIURETIC AGENT; DONEPEZIL; FLUOXETINE; GALANTAMINE; ISOENZYME; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHENYTOIN; RIFAMPICIN; RIVASTIGMINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRAIN CORTEX; BRAIN REGION; BRAIN STEM; CAUDATE NUCLEUS; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FOOD INTAKE; HIPPOCAMPUS; HUMAN; LEWY BODY; MAINTENANCE THERAPY; MEDULLA OBLONGATA; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; URINE INCONTINENCE; VOMITING;

CARBAMATES; CHOLINESTERASE INHIBITORS; DEMENTIA; GALANTAMINE; HUMANS; INDANS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES;

EID: 0036063785     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Alzheimer's disease
2. Selective loss of central cholinergic neurons in Alzheimer's disease
3. The cholinergic hypothesis of geriatric memory dysfunction
4. New perspectives on the neurochemical changes of Alzheimer's disease
5. Cholinesterase inhibitors: A new class of psychotropic compounds
6. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition
7. Acetylcholinesterase may have novel functions in the brain
8. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system
9. Selectivity of cholinesterase inhibition
10. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - A study of molecular forms
11. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain
12. Clinical development of Exelon™ (ENA-713): The ADENA® programme
13. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy in Alzheimer's disease
14. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review
15. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
16. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action
17. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action - A hypothesis
18. Dose-dependent CSF acetylcholinesterase inhibition with SDZ ENA 713 in Alzheimer's disease
19. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment
20. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease
21. Clinical pharmacology of rivastigmine: A new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
22. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors
23. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia
24. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine
25. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
26. Limited inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex
27. Polypharmacy in the elderly: Clinical implications
28. E2020 - The pharmacology of a piperidine cholinesterase inhibitor
29. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
30. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
31. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine
32. A 5-month, randomized, placebo-controlled trial of galantamine in AD
33. Galantamine: Additional benefits to patients with Alzheimer's disease
34. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR
35. Allosteric sensitization of nicotinic receptors by galantamine, treatment strategy for Alzheimer's disease
36. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
37. Galantamine in AD: A 6-month randomized, placebo-controlled trial with 6-month extension
38. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
39. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
40. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial
41. A large-scale, open-label trial of donepezil in the treatment of Alzheimer's disease: Side-effects and concomitant medication use
42. Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients
43. Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up
44. Tolerability profiles of AChEls: A critical component of care for Alzheimer's disease patients
45. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
46. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild-moderate AD
47. A randomised double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
48. Violent behaviour associated with donepezil
49. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome
50. Adverse effects associated with the use of donepezil in general practice in England
51. Behavioral complications associated with donepezil
52. Donepezil: Suspected adverse reations
53. Convulsions induced by donepezil
54. Donepezil therapy in clinical practice: A randomized crossover study
55. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial
56. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
57. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial
58. Effects of two-year treatment with cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer's disease
59. Extrapyramidalism in Alzheimer's disease: Prevalence, psychiatric, and neuropsychological correlates
60. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease
61. Determinants of spontaneous extrapyramidal symptoms in elderly psychiatric inpatients diagnosed with Alzheimer's disease, major depressive disorder, or psychotic disorders
62. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
63. Donepezil in dementia with Lewy bodies: Treatment and withdrawal
64. Possible association between donepezil and worsening Parkinson's disease
65. Extrapyramidal side effects in a patient treated with risperidone plus donepezil
66. Parkinsonian onset in a patient concurrently using tiapride and donepezil
67. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double blind, placebo-controlled international study
68. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
69. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease
70. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons
71. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study
72. The effects of donepezil in patients with Alzheimer's disease - Results from a multinational trial
73. Comparison of the tolerability, ease of use and efficacy of donepezil and Exelon® in Alzheimer's disease patients: A 12-week multinational study
74. Aricept-induced nightmares in Alzheimer's disease: 2 case reports
75. Results of clinical studies with donepezil in vascular dementia
76. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep
77. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials
78. Galantamine reduces slow wave sleep. Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence
79. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor
80. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man
81. Increases in number of REMS and REM density in humans following an intensive learning period
82. Human hippocampal long-term sustained response during word memory processing
83. Human hippocampus associates information in memory
84. Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial
85. Donepezil use in Alzheimer disease
86. Rivastigmine for the treatment of dementia associated with Parkinson's disease: A case series
87. Urinary incontinence: An unrecognized adverse effect with donepezil
88. Symptomatic sinus bradycardia associated with donepezil
89. Electrocardiographic effects of rivastigmine
90. An efficacy and safety analysis of Exelon® in Alzheimer's disease patients with concurrent vascular risk factors
91. Treatment of symptoms specific to patients with subcortical vascular dementia: An open label pilot study comparing rivastigmine and cardioaspirin
92. Donepezil overdose: A tenfold dosing error
93. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors
94. Effect of drug interactions on healthcare costs for donepezil patients
95. Extra-pyramidal syndrome induced by donepezil
96. Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: A 26-week follow-up
97. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease
98. Antiemetics mitigate nausea and vomiting in Alzheimer's patients receiving rivastigmine
99. Central mechanisms for apomorphine-induced emesis in the dog
100. Drugs five years later. Bromocriptine
101. New treatments of Alzheimer disease: A review
102. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain
103. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase
104. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine
105. Acetylcholine as a brain state modulator: Triggering and long-term regulation of REM sleep
106. Regional spectral analysis of the REM sleep EEG in mild to moderate Alzheimer's disease
107. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
108. Switching cholinesterase inhibitors in patients with Alzheimer's disease
109. Switching acetylcholinesterase inhibitor therapy in AD